COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase I Study of Lintuzumab-Ac225 in Combination with CLAG-M Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Protocol No
IIT-ABEDIN-LINTUZUMAB-AML
Principal Investigator
Sameem Abedin
Phase
I
Summary
In this study, we want to find out more about the side effects (problems and symptoms) of a new drug, Lintuzumab-Ac225 in combination with CLAG-M (cladribine, cytarabine, filgrastim, Mitoxantrone) and what doses are safe for people to take. Everyone in this study will receive Lintuzumab-Ac225 and combination with CLAG-M. While CLAG-M is an approved regimen for RR-AML, Lintuzumab-Ac225 is still experimental and is not approved by the U.S. Food and Drug Administration .
Description
Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL